Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.

Biomarker brain atrophy magnetic resonance imaging multiple sclerosis prognosis serum neurofilament light chain

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 15 12 2020
medline: 26 10 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage. This was a post hoc analysis of longitudinal data and samples from the ADVANCE trial (NCT00906399) of patients with relapsing-remitting MS (RRMS). sNfL was measured every 3 months for 2 years, then every 6 months for 4 years. Regression models explored how sNfL data predicted 4-year values of brain volume, expanded disability status scale score, and T2 lesions. sNfL levels were assessed in those receiving placebo, peginterferon beta-1a, and those with disease activity. Baseline sNfL was a predictor of 4-year brain atrophy and development of new T2 lesions. Clinical ( These data support sNfL as a prognostic and disease-monitoring biomarker for RRMS.

Identifiants

pubmed: 33307998
doi: 10.1177/1352458520972573
pmc: PMC8414824
doi:

Substances chimiques

Neurofilament Proteins 0

Banques de données

ClinicalTrials.gov
['NCT00906399']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1497-1505

Références

Mult Scler. 2015 Jul;21(8):1025-35
pubmed: 25432952
Neurology. 2020 Mar 17;94(11):e1201-e1212
pubmed: 32047070
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
Mult Scler Relat Disord. 2019 Jan;27:133-138
pubmed: 30384198
BMC Neurol. 2014 Mar 25;14:58
pubmed: 24666846
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
JAMA Neurol. 2019 Nov 1;76(11):1359-1366
pubmed: 31403661
Bioanalysis. 2019 Aug;11(15):1405-1418
pubmed: 31401845
Mult Scler Relat Disord. 2019 Oct;35:228-232
pubmed: 31404762
Mult Scler. 2014 Sep;20(10):1355-62
pubmed: 24515731
Lancet Neurol. 2014 Jul;13(7):657-65
pubmed: 24794721
Mult Scler. 2020 Nov;26(13):1691-1699
pubmed: 31680621
Neurology. 2015 Feb 24;84(8):784-93
pubmed: 25632085
Nat Rev Neurol. 2015 Oct;11(10):597-606
pubmed: 26369511
Nat Commun. 2020 Feb 10;11(1):812
pubmed: 32041951
JAMA Neurol. 2016 Jan;73(1):60-7
pubmed: 26524180
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Mult Scler. 2020 Nov;26(13):1670-1681
pubmed: 31610732
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
AJNR Am J Neuroradiol. 2016 Mar;37(3):394-401
pubmed: 26564433
Lancet Neurol. 2006 Feb;5(2):158-70
pubmed: 16426992
JAMA Neurol. 2020 Jan 1;77(1):58-64
pubmed: 31515562
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089
pubmed: 31211172
Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143
pubmed: 30181778
Brain. 2001 Sep;124(Pt 9):1803-12
pubmed: 11522582
Mult Scler Relat Disord. 2018 Feb;20:231-238
pubmed: 29579629
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1324-1330
pubmed: 31611264
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753

Auteurs

Peter A Calabresi (PA)

Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Douglas L Arnold (DL)

Montreal Neurological Institute, McGill University, Montreal, QC, Canada/NeuroRx, Montreal, QC, Canada.

Dipen Sangurdekar (D)

Biogen, Cambridge, MA, USA.

Carol M Singh (CM)

Biogen, Cambridge, MA, USA.

Arman Altincatal (A)

Biogen, Cambridge, MA, USA.

Carl de Moor (C)

Biogen, Cambridge, MA, USA.

Bob Engle (B)

Biogen, Cambridge, MA, USA.

Jaya Goyal (J)

Biogen, Cambridge, MA, USA.

Aaron Deykin (A)

Biogen, Cambridge, MA, USA.

Suzanne Szak (S)

Biogen, Cambridge, MA, USA.

Bernd C Kieseier (BC)

Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany/Biogen, Cambridge, MA, USA.

Richard A Rudick (RA)

Biogen, Cambridge, MA, USA.

Tatiana Plavina (T)

Biogen, Cambridge, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH